NYSE:PKI - PerkinElmer Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $85.50 +1.44 (+1.71 %) (As of 05/22/2019 07:31 AM ET)Previous Close$84.06Today's Range$84.33 - $85.8452-Week Range$71.31 - $103.00Volume1.05 million shsAverage Volume668,083 shsMarket Capitalization$9.48 billionP/E Ratio23.68Dividend Yield0.33%Beta1.22 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts. Receive PKI News and Ratings via Email Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorComputer and Technology Current SymbolNYSE:PKI Previous Symbol CUSIP71404610 CIK31791 Webhttp://www.perkinelmer.com/ Phone781-663-6900Debt Debt-to-Equity Ratio0.70 Current Ratio1.68 Quick Ratio1.17Price-To-Earnings Trailing P/E Ratio23.68 Forward P/E Ratio21.11 P/E Growth1.52 Sales & Book Value Annual Sales$2.78 billion Price / Sales3.41 Cash Flow$5.4183 per share Price / Cash Flow15.78 Book Value$23.79 per share Price / Book3.59Profitability EPS (Most Recent Fiscal Year)$3.61 Net Income$237.93 million Net Margins8.89% Return on Equity15.98% Return on Assets6.90%Miscellaneous Employees12,500 Outstanding Shares110,918,000Market Cap$9.48 billion Next Earnings Date8/7/2019 (Estimated) OptionableOptionable PerkinElmer (NYSE:PKI) Frequently Asked Questions What is PerkinElmer's stock symbol? PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI." How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer? PerkinElmer announced a quarterly dividend on Thursday, April 25th. Investors of record on Friday, July 19th will be given a dividend of $0.07 per share on Friday, August 9th. This represents a $0.28 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, July 18th. View PerkinElmer's Dividend History. How were PerkinElmer's earnings last quarter? PerkinElmer, Inc. (NYSE:PKI) issued its quarterly earnings data on Thursday, April, 25th. The medical research company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.66 by $0.03. The medical research company had revenue of $648.70 million for the quarter, compared to analysts' expectations of $645.38 million. PerkinElmer had a return on equity of 15.98% and a net margin of 8.89%. The company's revenue was up .7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. View PerkinElmer's Earnings History. When is PerkinElmer's next earnings date? PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for PerkinElmer. What guidance has PerkinElmer issued on next quarter's earnings? PerkinElmer updated its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of $4.02-4.07 for the period, compared to the Thomson Reuters consensus estimate of $4.03. What price target have analysts set for PKI? 15 analysts have issued 12-month target prices for PerkinElmer's stock. Their forecasts range from $41.00 to $115.00. On average, they anticipate PerkinElmer's share price to reach $80.7308 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View Analyst Price Targets for PerkinElmer. What is the consensus analysts' recommendation for PerkinElmer? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 10 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer. Has PerkinElmer been receiving favorable news coverage? News coverage about PKI stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PerkinElmer earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of PerkinElmer's key competitors? Some companies that are related to PerkinElmer include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO) and HTG Molecular Diagnostics (HTGM). What other stocks do shareholders of PerkinElmer own? Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include Celgene (CELG), Cisco Systems (CSCO), Honeywell International (HON), Pentair (PNR), Square (SQ), AbbVie (ABBV), CVS Health (CVS), General Electric (GE), Thermo Fisher Scientific (TMO) and Illumina (ILMN). Who are PerkinElmer's key executives? PerkinElmer's management team includes the folowing people: Mr. Robert F. Friel, Chairman & CEO (Age 63)Dr. Prahlad R. Singh, Pres & COO (Age 54)Mr. James M. Mock, Sr. VP & CFO (Age 42)Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56) Who are PerkinElmer's major shareholders? PerkinElmer's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Select Equity Group L.P. (7.83%), BlackRock Inc. (6.02%), Janus Henderson Group PLC (5.71%), Primecap Management Co. CA (2.63%), King Luther Capital Management Corp (2.23%) and Pictet Asset Management Ltd. (1.97%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer. Which institutional investors are selling PerkinElmer stock? PKI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Primecap Management Co. CA, Pictet Asset Management Ltd., Morgan Stanley, Wells Fargo & Company MN, Select Equity Group L.P., Public Employees Retirement Association of Colorado and Janus Henderson Group PLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Insider Buying and Selling for PerkinElmer. Which institutional investors are buying PerkinElmer stock? PKI stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Geode Capital Management LLC, Schonfeld Strategic Advisors LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Jefferies Group LLC, Charles Schwab Investment Management Inc. and SEI Investments Co. View Insider Buying and Selling for PerkinElmer. How do I buy shares of PerkinElmer? Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is PerkinElmer's stock price today? One share of PKI stock can currently be purchased for approximately $85.50. How big of a company is PerkinElmer? PerkinElmer has a market capitalization of $9.48 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe. What is PerkinElmer's official website? The official website for PerkinElmer is http://www.perkinelmer.com/. How can I contact PerkinElmer? PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected] MarketBeat Community Rating for PerkinElmer (NYSE PKI)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 414 (Vote Outperform)Underperform Votes: 432 (Vote Underperform)Total Votes: 846MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Options Trading Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.